Group 1 - The core point of the article is that Minsheng Health has repurchased approximately 1.34 million shares, accounting for 0.38% of its total share capital, with a total expenditure of about 17.5 million yuan [1][1][1] - The share repurchase was conducted through a special securities account via centralized bidding, with the highest transaction price at 14.03 yuan per share and the lowest at 11.83 yuan per share [1][1][1] - As of the report date, Minsheng Health's market capitalization stands at 4.9 billion yuan [1][1][1] Group 2 - For the first half of 2025, Minsheng Health's revenue composition shows that vitamin and mineral supplements account for 92.15% of total revenue, while other businesses contribute 7.85% [1][1][1]

Group 1 - The core point of the article is that Minsheng Health (SZ 301507) announced the results of its board meeting held on August 22, 2025, where the 2025 semi-annual report and its summary were reviewed [1] - For the first half of 2025, Minsheng Health's revenue composition shows that vitamin and mineral supplements accounted for 92.15% of total revenue, while other businesses contributed 7.85% [1] - As of the time of reporting, Minsheng Health has a market capitalization of 5.5 billion yuan [1] Group 2 - The article also mentions a separate initiative where a veterinary medicine PhD is cultivating crops on 25,000 acres in Africa, achieving a yield of 250 jin per acre in the first season, with plans to expand to 100,000 acres [1] - The initiative is looking to hire individuals with a monthly salary ranging from 10,000 to 20,000 yuan [1]

Group 1 - Minsheng Health (SZ 301507, closing price: 15.52 CNY) announced on August 19 that its subsidiary, Minsheng Zhongke Jiayi (Shandong) Bioengineering Co., Ltd., received an invention patent certificate from the National Intellectual Property Administration for a strain of Lactobacillus curvatus JYLU-88 that promotes EGF and EGFR expression [2] - For the fiscal year 2024, Minsheng Health's revenue composition is as follows: vitamin and mineral supplements account for 96.91%, other health products for 1.93%, probiotics for 0.66%, other businesses for 0.39%, and therapeutic drugs for 0.11% [2]

Core Viewpoint - Minsheng Health announced a share buyback plan, having repurchased approximately 1.33 million shares, representing 0.37% of the total share capital, with a total expenditure of around 17.26 million yuan [2] Summary by Category Share Buyback - As of July 31, 2025, Minsheng Health has repurchased about 1.33 million shares through a special securities account via centralized bidding, with a maximum transaction price of 13.82 yuan per share and a minimum transaction price of 11.83 yuan per share [2] Revenue Composition - For the year 2024, the revenue composition of Minsheng Health is as follows: - Vitamin and mineral supplements account for 96.91% - Other health products account for 1.93% - Probiotics account for 0.66% - Other businesses account for 0.39% - Therapeutic drugs account for 0.11% [2]